
	Where results make sense

Topic: Heart protection study

Related Topics

Statin

In the News (Wed 23 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	NHF Research in Coronary Heart Disease
		This study shows that people who've had a heart attack or stroke, or who are at risk of one, benefit substantially from statin treatment even if their cholesterol levels do not appear to be elevated.
		The effect on heart patients of antioxidant vitamins was also studied; no benefits were shown within the course of the study from administration of vitamins E, C or beta-carotene compared with placebo.
		This was a qualitative study of eighteen mothers (72% fl and with an average age of 25 years) of pre-school children in an urban area of the USA.
	www.heartforum.org.uk /research.html (2914 words)

	Heart Protection Study (Site not responding. Last check: 2007-10-22)
		Observational studies in different populations indicate a continuous positive relationship between coronary heart disease risk and blood LDL cholesterol concentration that extends well below the range currently seen in Western populations, without any definite "threshold" below which a lower concentration is not associated with lower risk.
		During the early part of the study, participants who were prescribed a non-study statin were routinely advised to stop their study simvastatin or placebo tablets.
		Based on previous studies in similar populations, it was estimated that there might be about 1500 coronary deaths, plus similar numbers of non-fatal myocardial infarctions, among 20 000 such patients followed for an average of 5 years.
	www.ciitn.missouri.edu /testsite/www/212w03ISPR/group29_article2.html (3347 words)

	New Page 0
		The results of the Heart Protection Study (HPS) were presented at the American Heart Association Scientific Sessions 2001 meeting in Anaheim, California.
		The study involved 20,536 individuals, aged 40-80 years, who were at high risk of development of coronary heart disease (CHD), but for whom the benefit of HMG-CoA reductase inhibitor or "statin" therapy was still uncertain.
		In addition, the results of the study may result in a lowering of target cholesterol levels or the elimination of the concept of an LDL level at which to initiate therapy with statins.
	www.uic.edu /pharmacy/services/di/hps.htm (665 words)

	Globeinvestor.com: Newly Published Results of Landmark Heart Protection Study with ZOCOR 40 mg Show Benefits for People ...
		The Heart Protection Study is the first study designed to investigate the benefits of therapy with ZOCOR 40 mg in people with Type I and Type II diabetes with or without a prior history of heart disease or high cholesterol.
		The Heart Protection Study (HPS) was a large, multi-center, placebo-controlled, double-blind study with a mean duration of 5 years conducted in 20,536 patients (10,269 on ZOCOR 40 mg and 10,267 on placebo).
		In the Multicenter Anti-Atheroma Study, the effect of simvastatin on atherosclerosis was assessed by quantitative coronary angiography in hypercholesterolemic patients with coronary heart disease.
	www.globeinvestor.com /servlet/WireFeedRedirect?cf=GlobeInvestor/config&vg=BigAdVariableGenerator&date=20030612&archive=bwire&slug=231635619 (9540 words)

	MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised ...
		The Heart Protection Study provides further evidence about the effects of these three antioxidant vitamins on vascular and non-vascular mortality and major morbidity by assessing 5 years of their supplementation in a large number of high-risk individuals.
		The non-randomised observational studies that found a lower incidence of cardiovascular events to be associated with higher intakes of different antioxidant vitamins were chiefly of people without known coronary or other vascular disease, and it has been suggested that these vitamins might be protective only before occlusive disease has developed.
		The daily dose of 600 mg of vitamin E tested in the Heart Protection Study is greater than the amounts that have been associated, in non-randomised observational studies, with 20-40% proportional reductions in the incidence of coronary events.
	www.vaccinationnews.com /DailyNews/2003/June/25/MRC-BHFHeartProtection25.htm (6502 words)

	Heart Protection Study
		In that study, a cholesterol reduction of about 1.5 mmol/l was maintained for about 10 years, and there was a significant 35%±10 reduction in total CHD (and a promising, though not significant, 28%±18 reduction in fatal CHD).
		Moreover, by combining the results from this study with those from the other main randomised trials of cholesterol-lowering in a collaborative overview, it should be possible to assess directly the effects of lowering cholesterol on total mortality and on fatal CHD in some of the larger subgroups of interest.
		In this 2x2 factorial study with 6 years of treatment, a low daily dose of vitamin E was not shown to have protective effects and a standard daily dose of beta-carotene appeared, if anything, to have some possible adverse effects.
	www.heartprotection.nl /pages/option10/section1.html (4713 words)

	Zocor (Simvastatin) Saves Lives In High-Risk Patients, Regardless Of Cholesterol Level, Study In Lancet Shows - ...
		The 69-hospital U.K. study demonstrated highly significant results at its primary endpoints by reducing the risk of death from all causes by 13 per cent and of death from coronary heart disease (CHD) by 18 per cent.
		With nearly 6,000 diabetes patients enrolled in the Heart Protection Study, it is the first trial designed to investigate the benefits of cholesterol-lowering therapy in Type 1 and Type 2 diabetics, with or without a prior history of heart disease or high cholesterol.
		In a separate component of the study, similar effects of antioxidant therapy (vitamins C and E and beta-carotene) in simvastatin versus placebo patients were evaluated.
	www.docguide.com /dg.nsf/PrintPrint/6F1EE839E9D4F81C85256BED00520D3D (1440 words)

	The International Network of Cholesterol Skeptics
		We are questioning the wisdom of recommending statin treatment for a large segment of the world’s population simply because they have elevated lipid levels or are assumed to be at increased risk for coronary events because of the presence of other risk markers.
		MRC/BHF heart protection study of cholesterol lowering in 20 536 high-risk individuals: a randomised placebo-controlled trial.
		Sir-The authors of the Heart Protection Study state that its size provides "considerable reassurance" that long term simvastatin therapy to lower cholesterol is unlikely to induce cancer.1 However, we believe that an important aspect of this potentially serious problem has been overlooked.
	www.thincs.org /unpublic.LancetHPS.htm (868 words)

	Heart Protection
		But, new findings from the UK’s 20,000-patient Heart Protection Study show that statins also cut the risks of heart attacks and strokes in people who have diabetes, or have narrowing of arteries in their legs, or have had a stroke.
		By deliberately studying large numbers of older people, the researchers were able to show that cholesterol-lowering with statins was just as effective for the over 70s as for those in middle age.
		One of the most encouraging aspects of the study was that the majority of people now shown to benefit from statins would already be known to their doctors because of their past medical history.
	www.mrc.ac.uk /prn/index/public-interest/public-news/public-heart_protection.htm (964 words)

	Vitamin C protection against heart disease doubted (Site not responding. Last check: 2007-10-22)
		While studies of a cross-section of a population have tied vitamin C intake to coronary heart disease, controlled trials to see if vitamin C wards off heart trouble have shown no effect, Dr. Debbie A. Lawlor of the University of Bristol and colleagues note in the medical journal Heart.
		The researchers previously suggested that high levels of vitamin C might be related to higher socioeconomic class in childhood and adult life.
		Specifically, the rate of coronary heart disease was the equivalent of 13.2 cases per 1,000 women per year for women with zero to four adverse socioeconomic indicators and 15.2 per 1,000 for women with five or more adverse indicators.
	www.dental.am /heart-disease/18212_0_22_0_C (465 words)

	BHF Health Professionals - Factfiles: 7-2003: The Medical Research Council (MRC) / British Heart Foundation (BHF) Heart ...
		The Heart Protection Study (HPS) is a large randomised trial of cholesterol-lowering using simvastatin and of anti-oxidant vitamin supplementation using vitamins E, C and beta-carotene, in 20,000 people at increased risk of coronary heart disease.
		Observational studies over many years have indicated that, throughout the range, higher blood cholesterol levels are associated with greater risk of coronary heart disease (CHD), but with other factors (such as blood pressure, smoking and history of other disease) also determining a particular individual’s risk of CHD.
		During the study, about one third of participants allocated placebo and a similar number of those allocated simvastatin complained of muscle pain at some time, but myopathy (muscle symptoms with raised creatine kinase values >10 times the upper limit of normal) was very rare.
	www.bhf.org.uk /professionals/index.asp?secID=15&secondlevel=471&thirdlevel=759&artID=3804 (1450 words)

	Find out about the Heart Protection Study at heartprotectionstudy.com (Site not responding. Last check: 2007-10-22)
		The purpose of the Heart Protection Study was to explore whether lowering cholesterol provides benefits to a wide range of people at high risk for coronary events.
		The Study was the largest of its kind, researching groups who had not previously been extensively studied.
		The Heart Protection Study was designed, conducted, analyzed, and reported by Oxford University and funded in part by Merck & Co., Inc.
	www.zocor.com /simvastatin/zocor/consumer/heartprotectionstudy/index.jsp (252 words)

	HPS Information
		The MRC/BHF Heart Protection Study is much the largest trial in the world of cholesterol-lowering therapy and of antioxidant vitamin supplementation in people at increased risk of heart disease.
		In addition, within each of these two groups (using a "factorial" design), half were allocated to receive antioxidant vitamins (600 mg E, 250 mg C and 20 mg beta-carotene daily), and half to receive placebo capsules.
		Consequently, the MRC/BHF Heart Protection Study provides reliable evidence about the effects of these cholesterol-lowering treatments and antioxidant vitamin supplements on mortality and major morbidity in a wide range of circumstances.
	www.ctsu.ox.ac.uk /~hps (332 words)

	PJ Online \| News: Call for change to guidelines following publication of Heart Protection Study
		Guidelines on the management of coronary heart disease should be changed so that a statin is considered for anybody at increased risk of heart attack or stroke regardless of their blood cholesterol level.
		In the study, 20,536 adults with coronary heart disease, arterial disease or diabetes were randomly assigned to receive either 40mg simvastatin or placebo daily for five years.
		The Heart Protection Study also assessed the effects of using antioxidant vitamin supplements (600mg vitamin E, 250mg vitamin C and 20mg beta-carotene daily) in people at high risk of vascular disease.
	www.pharmj.com /Editorial/20020706/news/callforchange.html (461 words)

	Diabetes Monitor - the heart protection study
		The study found that statin drugs cut the risk of heart attacks, strokes and the need for angioplasty or bypass surgery in people with diabetes by one-third.
		The present study provides direct evidence that cholesterol-lowering therapy is beneficial for people with diabetes even if they do not already have manifest coronary disease or high cholesterol concentrations.
		For example, among the type of diabetic patient studied without occlusive arterial disease, 5 years of treatment would be expected to prevent about 45 people per 1000 from having at least one major vascular event (and, among these 45 people, to prevent about 70 first or subsequent events during this treatment period).
	diabetesmonitor.com /statins.htm (615 words)

	Lancet study finds no health benefit from antioxidants supplements in high-risk individuals
		The study participants ranged from 40 to 80 years of age, and all were ill: 41% had previous experienced a heart attack and 24% had other coronary disease.
		Although 41% of the study population had treated hypertension, only 1% were included in the study on the basis of this finding alone.
		The study also found small but highly significant increases total cholesterol, LDL cholesterol, and triglycerides in the vitamin group's blood serum.
	www.supplementquality.com /efficacy/Lancet_antiox_null.html (337 words)

	HPS Information
		To help resolve these uncertainties, the MRC/BHF Heart Protection Study was designed to be really large, to involve a substantial reduction in blood LDL cholesterol levels and a substantial increase in antioxidant vitamin levels, and to include a wide range of patients at substantial risk of death from heart disease and other causes.
		Between July 1994 and May 1997, 20,536 individuals were recruited in 69 hospitals from within various prior disease categories (coronary disease, other occlusive arterial disease, diabetes, hypertension) and other categories (women, the elderly, those with average or below average cholesterol levels) where there was uncertainty as to how worthwhile, and safe, are these treatments.
		Compliance with the study treatments was good, resulting in large average reductions in blood levels of total cholesterol (1.2 mmol/l) and LDL cholesterol (1.0 mmol/l), and large increases in antioxidant vitamin levels.
	rum.ctsu.ox.ac.uk /~hps (332 words)

	heart protection study zocor: Get inline information Zocor Prescription, lowestprices, heart protection study zocor ... (Site not responding. Last check: 2007-10-22)
		attack heart zocor zocor zocor 40mg or zocor trial z zocor is requid zocor 80mg zocor end zocor alternative zocor end generic zocor.
		Search heart protection study zocor on the manufacturer zocor off gain weight zocor.
		Usually interaction zocor is requid zocor 40mg information zocor canada on the lipitor versus zocor and zocor study.
	tabletse.com /heart-protection-study-zocor.html (494 words)

	CNN.com - This week in the medical journals - May 12, 2005
		A study by researchers at the Minneapolis Heart Institute Foundation, published in Circulation, a journal of the American Heart Association, found aneurysms in more than 30 percent of cocaine abusers while in nonusers the aneurysm rate was less than eight percent.
		Likewise, men who could not increase their heart rate by at least 89 beats a minute during exercise testing had a risk of sudden death that was four times greater than men who increased their heart rate by 113 beats per minute during exercise.
		Heart rate is controlled by the autonomic nervous system -- the body's "unconscious" wiring that controls all organ functions -- and the researchers suggested that an exercise-training program might re-wire the system to reduce the sudden death risk.
	www.cnn.com /2005/HEALTH/05/12/journal.roundup/index.html (1152 words)

	MRC/BHF Heart Protection Study
		The aim of the Heart Protection Study [1, 2, 3, 4] was to assess reliably the effects of cholesterol-lowering therapy and antioxidant vitamin supplementation on morbidity and mortality in patients with a wide range of different categories of high risk.
		In addition, epidemiological studies have shown an inverse relationship between both dietary intake and plasma levels of antioxidant vitamins and the incidence of coronary heart disease and cancer.
		This study was large enough to allow sensible analyses to be performed on different subcategories of patients.
	www.jr2.ox.ac.uk /bandolier/booth/cardiac/HPS.html (1089 words)

	The Heart Protection Study and Other Developments in Atherosclerosis
		Although prior studies have suggested -- based on post-hoc analysis, meta-analysis, and even in some cases as a predefined prospective end point -- that statins decreased stroke event rates, the epidemiologic database prior to HPS had not suggested that total cholesterol levels were a strong predictor of stroke risk.
		Earlier basic science studies had suggested that perhaps CRP is not simply a marker for, but also a mediator of, inflammatory processes in the vasculature, and this theory is now supported by reports that CRP may increase uptake of oxidized LDL.
		The increasing interest in the role of PPARs and nuclear receptors in vascular biology and atherosclerosis was evident at the AHA meeting, as reflected by the focus on this topic in 3 of the sessions.
	www.thaiheart.org /aha2001/heart_protection_study_and_other.htm (2312 words)

	McCormack, J. Heart Protection Study - Use of Simvastatin in "High Risk" Individuals. J Inform Pharmacother ... (Site not responding. Last check: 2007-10-22)
		McCormack, J. Heart Protection Study - Use of Simvastatin in "High Risk" Individuals.
		MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,356 high-risk individuals: a randomized placebo-controlled trial.
		This study shows that simvastatin given to "high risk" patients, regardless of age or sex, or baseline cholesterol levels lowers the chance of cardiovascular events.
	www.informedpharmacotherapy.com /Issue10/EBSS/heart%20protection%20study.htm (218 words)

	ABC News: Statins Do More Than Lower Cholesterol (Site not responding. Last check: 2007-10-22)
		A new study in diabetic rats suggests that statin treatment also prevents or reverses damage to the delicate endothelial cells that line arteries, according to researchers from the Medical College of Georgia, in Augusta.
		Researchers in that study found that diabetics who took a daily dose of simvistatin (Zocor) were 27 percent less likely to have a first heart attack, and 24 percent less likely to have a stroke, than those who did not take the drug — regardless of their blood cholesterol or sugar levels.
		The animal studies are being extended because "we'd like to learn more about the role of statins in reducing inflammation," he said.
	abcnews.go.com /Health/Healthology/story?id=636307 (540 words)

	Prevention of coronary heart disease: Statins are even less effective than paper shows -- Taylor et al. 328 (7436): 404 ...
		Prevention of coronary heart disease: Statins are even less effective than paper shows -- Taylor et al.
		of the heart protection study lend even more weight to his scepticism.
		Heart protection study of cholesterol lowering therapy and antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience.
	bmj.bmjjournals.com /cgi/content/full/328/7436/404-a (358 words)

Try your search on: Qwika (all wikis)